Zacharon Pharmaceuticals
Zacharon Pharmaceuticals employs its glycobiology expertise to develop a new class of human therapeutics targeting glycans.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD3—5m (Dealroom.co estimates Jun 2010.)
San Diego California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Grant | ||
| N/A | $500k | Seed | |
| N/A | $33.0k | Convertible | |
N/A | Acquisition | ||
| Total Funding | AUD824k | ||